Paul A Dickinson

Citado por

	Total	Desde 2020
Citas	4915	1817
Índice h	27	16
Índice i10	40	22

620

310

155

465

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202513 15 9 27 41 42 41 41 64 45 82 90 148 223 539 610 529 475 409 400 366 304 285 52

Acceso público

Ver todo

0 artículos

2 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Anette MullertzBioneer:FARMA, Department of Pharmacy, University of CopenhagenDirección de correo verificada de sund.ku.dk
Jennifer DressmanGoethe UniversityDirección de correo verificada de em.uni-frankfurt.de
Hitesh MistryUniversity of ManchesterDirección de correo verificada de manchester.ac.uk
Helena ThörnMedical doctor at Sahlgrenska University hospitalDirección de correo verificada de vgregion.se
Glen ClackSenior Medical Director, AstraZenecaDirección de correo verificada de astrazeneca.com
R Donald Harvey, PharmD, BCOP, FC...Emory University School of Medicine and Winship Cancer InstituteDirección de correo verificada de emory.edu
Richard BarkerAssociate Principle Scientist, AstraZenecaDirección de correo verificada de astrazeneca.com
Maria VertzoniNational and Kapodistrian University of Athens, Department of Pharmacy, Associate ProfessorDirección de correo verificada de pharm.uoa.gr
Sandra KleinProfessor of Pharmaceutical Technology, Greifswald UniversityDirección de correo verificada de uni-greifswald.de
Joachim BrouwersKU LeuvenDirección de correo verificada de pharm.kuleuven.be
Werner WeitschiesUniversity of GreifswaldDirección de correo verificada de uni-greifswald.de
James ButlerGlaxoSmithKline, GSKDirección de correo verificada de gsk.com
James MannAstraZenecaDirección de correo verificada de astrazeneca.com
Abu SerajuddinProfessor of Industrial Pharmacy, St. John's UniversityDirección de correo verificada de stjohns.edu
Marilyn N. MartinezFDADirección de correo verificada de fda.hhs.gov
Peter Craig SevilleUniversity of WorcesterDirección de correo verificada de worc.ac.uk
Jake DickinsonAssociate Principal Scientist, Seda Pharmaceutical Development ServicesDirección de correo verificada de sedapds.com
Parviz GhahramaniInncelerex, Founder and Affiliate Professor, School of Pharmacy, University of Maryland, USADirección de correo verificada de inncelerex.com
Sudaxshina MurdanUCL School of PharmacyDirección de correo verificada de ucl.ac.uk
Hyungsuk KimAssociate Professor, Kwangwoon University, Seoul, KoreaDirección de correo verificada de kw.ac.kr

Seguir

Paul A Dickinson

Seda Pharmaceutical Development Services

Dirección de correo verificada de sedapds.com - Página principal

Biopharmaceutics Clinical Pharmacology Modelling


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer PA Jänne, JCH Yang, DW Kim, D Planchard, Y Ohe, SS Ramalingam, ... New England Journal of Medicine 372 (18), 1689-1699, 2015	2375	2015
In vitro models for the prediction of in vivo performance of oral dosage forms ES Kostewicz, B Abrahamsson, M Brewster, J Brouwers, J Butler, ... European Journal of Pharmaceutical Sciences 57, 342-366, 2014	425	2014
The effects of pharmaceutical excipients on drug disposition TR Buggins, PA Dickinson, G Taylor Advanced drug delivery reviews 59 (15), 1482-1503, 2007	178	2007
Clinical relevance of dissolution testing in quality by design PA Dickinson, WW Lee, PW Stott, AI Townsend, JP Smart, P Ghahramani, ... The AAPS journal 10, 380-390, 2008	173	2008
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies D Planchard, KH Brown, DW Kim, SW Kim, Y Ohe, E Felip, P Leese, ... Cancer Chemotherapy and pharmacology 77, 767-776, 2016	143	2016
An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence … PA Dickinson, R Abu Rmaileh, L Ashworth, RA Barker, WM Burke, ... The AAPS journal 14 (2), 196-205, 2012	125	2012
Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor PA Dickinson, MV Cantarini, J Collier, P Frewer, S Martin, K Pickup, ... Drug Metabolism and Disposition 44 (8), 1201-1212, 2016	119	2016
Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation AT Larsen, AG Ohlsson, B Polentarutti, RA Barker, AR Phillips, ... European Journal of Pharmaceutical Sciences 48 (1-2), 339-350, 2013	111	2013
The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance A Selen, PA Dickinson, A Müllertz, JR Crison, HB Mistry, MT Cruañes, ... Journal of Pharmaceutical Sciences 103 (11), 3377-3397, 2014	73	2014
Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors E Bergman, P Forsell, EM Persson, L Knutson, P Dickinson, R Smith, ... International journal of pharmaceutics 341 (1-2), 134-142, 2007	72	2007
An investigation of the disintegration of tablets in biorelevant media S Anwar, JT Fell, PA Dickinson International journal of pharmaceutics 290 (1-2), 121-127, 2005	72	2005
The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages BG Jones, PA Dickinson, M Gumbleton, IW Kellaway International journal of pharmaceutics 236 (1-2), 65-79, 2002	67	2002
Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans HA Thörn, A Lundahl, JA Schrickx, PA Dickinson, H Lennernäs European journal of pharmaceutical sciences 43 (3), 89-98, 2011	66	2011
Novel nanoparticles for pulmonary drug administration PA Dickinson, SW Howells, IW Kellaway Journal of drug targeting 9 (4), 295-302, 2001	61	2001
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib K Vishwanathan, PA Dickinson, K So, K Thomas, YM Chen, ... British journal of clinical pharmacology 84 (6), 1156-1169, 2018	58	2018
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - Results of two parallel first-in-human Phase I studies. A Omlin, RJ Jones, R van der Noll, T Satoh, M Niwakawa, SA Smith, ... Investigational New Drugs. 33 (3), 679-690., 2015	58	2015
The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non‐small‐cell lung cancer and in healthy volunteers K Vishwanathan, PA Dickinson, K Bui, PA Cassier, A Greystoke, E Lisbon, ... The Journal of Clinical Pharmacology 58 (4), 474-484, 2018	52	2018
Applications of physiologically based biopharmaceutics modeling (PBBM) to support drug product quality: a workshop summary report A Mitra, S Suarez-Sharp, XJH Pepin, T Flanagan, Y Zhao, E Kotzagiorgis, ... Journal of pharmaceutical sciences 110 (2), 594-609, 2021	49	2021
Particulate composition PA Dickinson, IW Kellaway, SW Howells US Patent 7,018,657, 2006	49	2006
Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383 BG Jones, PA Dickinson, M Gumbleton, IW Kellaway Journal of pharmacy and pharmacology 54 (8), 1065-1072, 2002	43	2002

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores